AD is characterized by numerous pathological alterations, including neuroinflammation, brain insulin resistance, synaptic dysfunction, and amyloid‐beta (Aβ)/tau‐mediated toxicity [10], and there is evidence that enhanced adiponectin signaling may reduce these pathologies [8, 11, 12]. The gene discussed is MAPT; the disease is Alzheimer disease.